Saito T, Wakui A, Yokoyama M, Himori T, Takahashi H, Kudo T, Takahashi K
Gan. 1977 Aug;68(4):375-87.
Clinical effect of 5-fluorouracil or chromomycin-A3 alone, 5-fluorouracil + chromomycin-A3, and of the first two plus prednisolone on gastrointestinal and other solid tumors was evaluated. Out of 133 cases acceptable for evaluation, the number of responders was as follows: 3 (18.8%) of 6 cases treated with 5-fluorouracil alone, 1 (9.1%) of 11 cases treated with chromomycin-A3 or chromomycin-A3 hemisuccinate, 13 (21.7%) of 60 cases on the two-drug regimen, and 21 (45.7%) of 46 cases on the three-drug regimen. In cases of stomach carcinoma, response rate to the three-drug regimen was 54.2% (13/24), significantly higher than that of other regimens. At least 25% regression in the size of primary tumor was observed in 2 (7.1%) of 28 cases on the two-drug regimen and in 6 (33.3%) of 18 cases on the three-drug regimen. Of 51 cases on the three-drug regimen, steroid diabetes developed in 5 cases, moon face in 4 cases, and gastric ulcer in 1 case. However, toxic effect of these regimens (especially appearance of leucopenia) was less than those of previously tried combined regimens. The duration of response, on an average, was 10.8 weeks in 13 cases on the two-drug regimen and 11.7 weeks in 21 cases on the three-drug regimen. It was concluded from these results that a better response is obtained by the three-drug regimen than other regimens, and that prednisolone in combination, in addition to its favorable effect in improving the general condition of the patients, might enhance the anticancer effect of the drugs used in combination.
评估了5-氟尿嘧啶或放线菌素A3单独使用、5-氟尿嘧啶+放线菌素A3以及前两者加泼尼松龙对胃肠道及其他实体瘤的临床疗效。在133例可进行评估的病例中，反应者数量如下：单独使用5-氟尿嘧啶治疗的6例中有3例（18.8%），使用放线菌素A3或放线菌素A3半琥珀酸酯治疗的11例中有1例（9.1%），两药联合方案治疗的60例中有13例（21.7%），三药联合方案治疗的46例中有21例（45.7%）。在胃癌病例中，三药联合方案的缓解率为54.2%（13/24），显著高于其他方案。两药联合方案治疗的28例中有2例（7.1%）、三药联合方案治疗的18例中有6例（33.3%）观察到原发肿瘤大小至少缩小25%。在三药联合方案治疗的51例中，5例出现类固醇糖尿病，4例出现满月脸，1例出现胃溃疡。然而，这些方案的毒性作用（尤其是白细胞减少的出现）比之前尝试的联合方案要小。两药联合方案治疗的13例平均缓解持续时间为10.8周，三药联合方案治疗的21例平均缓解持续时间为11.7周。从这些结果得出结论，三药联合方案比其他方案有更好的反应，并且泼尼松龙联合使用除了对改善患者一般状况有有利作用外，可能增强联合使用药物的抗癌效果。
